A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany

Use of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumour (NET) Patients in Germany - A Retrospective Evaluation in German Centers for NET (LUNET-2 Study)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07653126

Acronym

LUNET-2

Enrollment

117

Registered

2026-06-17

Start date

2023-04-03

Completion date

2023-09-29

Last updated

2026-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastro-enteropancreatic Neuroendocrine Tumor

Keywords

Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumors, GEP-NET, Peptide Receptor Radionuclide Therapy, PRRT, Lutetium-177, 177Lu-DOTATATE, Real World, Germany

Brief summary

The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with a confirmed diagnosis of GEP-NET (any localization of the primary tumor including cancer of unknown primary origin \[CUP\], any Grade). * Patients with a first cycle of primary PRRT of home-brew 177Lu-DOTATATE/DOTATOC or Lutathera® between 01 July 2020 and 30 June 2021.

Exclusion criteria

* Received a combination of PRRT with chemotherapy. * Received a combination of PRRT with a radionuclide other than lutetium-177 (e.g., yttrium-90).

Design outcomes

Primary

Measure	Time frame
Baseline Demographics	Baseline
Number of Patients by Tumor Status	Baseline
Duration Between Initial Diagnosis and Initiation of Primary PRRT	Baseline
Number of Patients by PRRT Line of Therapy	Approximately 1 year
Number of Patients by Type of PRRT Received	Approximately 1 year
PRRT Dosage	Approximately 1 year
Number of Patients by Treatment Interval	Approximately 1 year
Number of Patients by Co-medication	Approximately 1 year

Countries

Germany

Contacts

STUDY_DIRECTORNovartis Pharmaceuticals

Novartis Pharmaceuticals

Outcome results